Glenmark Pharma gets USFDA nod for acid reflux medication

PTI New Delhi | Updated on May 14, 2019 Published on May 14, 2019

Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for a generic version of AstraZeneca’s Nexium, used to treat acid reflux.

Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food & Drug Administration (US FDA) for someprazole magnesium delayed-release capsules USP in the strengths of 20 mg and 40 mg, the company said in a BSE filing.

The approved products are a generic version of AstraZeneca Pharmaceuticals’ Nexium delayed-release capsules.

Citing IQVIA sales data, Glenmark said, Nexium delayed-release capsules, 20 mg and 40 mg achieved annual sales of around $395.1 million in the 12-month period ended March 2019.

The company said its current portfolio consists of 153 products authorised for distribution in the US and 58 ANDA’s pending approval with the USFDA.

Shares of Glenmark Pharma were trading 0.46 per cent higher at Rs 594.35 apiece on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 14, 2019
This article is closed for comments.
Please Email the Editor